Centro de Investigaciones Biologicas (CIB-CSIC), Ramiro de Maetzu 9, Madrid, Spain; School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Avenida do Café, s/ n, 14040-903, Ribeirão Preto, SP, Brazil.
Centro de Investigaciones Biologicas (CIB-CSIC), Ramiro de Maetzu 9, Madrid, Spain.
Eur J Med Chem. 2018 Feb 10;145:431-444. doi: 10.1016/j.ejmech.2018.01.007. Epub 2018 Jan 5.
Alzheimer's disease (AD) is the most common form of dementia worldwide with an increasing prevalence for the next years. The multifactorial nature of AD precludes the design of new drugs directed to a single target being probably one of the reasons for recent failures. Therefore, dual binding site acetylcholinesterase (AChE) inhibitors have been revealed as cognitive enhancers and β-amyloid modulators offering an alternative in AD therapy field. Based on the dual ligands NP61 and donepezil, the present study reports the synthesis of a series of indolylpiperidines hybrids to optimize the NP61 structure preserving the indole nucleus, but replacing the tacrine moiety of NP61 by benzyl piperidine core found in donepezil. Surprisingly, this new family of indolylpiperidines derivatives showed very potent and selective hBuChE inhibition. Further studies of NMR and molecular dynamics have showed the capacity of these hybrid molecules to change their bioactive conformation depending on the binding site, being capable to inhibit with different shapes BuChE and residually AChE.
阿尔茨海默病(AD)是全球最常见的痴呆症形式,未来几年的患病率还会不断增加。AD 的多因素性质排除了针对单一靶点设计新药的可能性,这可能是最近失败的原因之一。因此,双重结合位点乙酰胆碱酯酶(AChE)抑制剂已被证明是认知增强剂和β-淀粉样蛋白调节剂,为 AD 治疗领域提供了一种替代方法。本研究基于双重配体 NP61 和多奈哌齐,合成了一系列吲哚基哌啶类杂合化合物,以优化 NP61 的结构,保留吲哚核,但用多奈哌齐中发现的苄基哌啶取代 NP61 的他克林部分。令人惊讶的是,这种新的吲哚基哌啶衍生物家族表现出非常强和选择性的 hBuChE 抑制作用。进一步的 NMR 和分子动力学研究表明,这些杂合分子能够根据结合位点改变其生物活性构象,能够以不同的形状抑制 BuChE 并残留抑制 AChE。